MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Phase 2 Terminated 35 enrolled Mirati Therapeutics Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

In this study, MGCD0103, a new anticancer drug under investigation, is given three times per week to elderly patients with previously untreated acute myelogenous leukemia/high risk myelodysplastic syndrome or adults with relapsed/refractory disease.

Timeline

Start: 2006-09
Primary completion: 2008-09
Completion: 2008-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mocetinostat	Small molecule	—	Oral

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Summary

Timeline

Drugs

Indications